Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
None
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.

  • 37 views
  • 29 May, 2021
  • 1 location
None
Dose Exploration Study OF JWCAR129 BCMA-Targeted CART for RRMM

maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
None
HB10101 Multiple Myeloma

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients

  • 0 views
  • 03 Feb, 2021
  • 1 location
None
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

  • 1 views
  • 26 Jan, 2021
  • 5 locations
None
Integrin 7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

According to the high expression of tumor cell-associated antigen CD138, integrin 7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T

  • 0 views
  • 26 Jan, 2021
  • 3 locations
None
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

  • 0 views
  • 31 May, 2021
  • 1 location
None
A Study of CC-99712 a BCMA Antibody-Drug Conjugate in Participants With Relapsed and Refractory Multiple Myeloma

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of …

measurable disease
electrophoresis
immunotherapeutic agent
refractory multiple myeloma
neutrophil count
  • 88 views
  • 28 Aug, 2021
  • 10 locations
None
Dose Escalation Study of Teclistamab a Humanized BCMA*CD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

multiple myeloma
estrogen
proteasome inhibitor
  • 292 views
  • 08 Dec, 2021
  • 16 locations
None
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

leukemia
measurable disease
bone marrow procedure
refractory multiple myeloma
bcma
  • 174 views
  • 14 Dec, 2021
  • 26 locations